Ory S J, Hammond C B, Yancy S G, Hendren R W, Pitt C G
Am J Obstet Gynecol. 1983 Mar 1;145(5):600-5. doi: 10.1016/0002-9378(83)91204-8.
Eight ovulatory women participated in the preliminary evaluation of a new method of contraception. The technique consisted of subdermal implantation of a biodegradable capsule capable of controlled release of levonorgestrel. The study spanned five menstrual cycles: three observation cycles to confirm ovulation, a cycle with the capsule implanted, and a follow-up observation cycle after its removal. All subjects who were sexually active relied on barrier contraception during the study. Basal body temperature determinations were made throughout all five cycles, and the last three cycles included serum assays of luteinizing hormone, follicle-stimulating hormone, estradiol, progesterone, and levonorgestrel on days 5, 8 to 18, and 22. All subjects except one experienced suppression of ovulation while the capsule was in place. No serious adverse effects were encountered. These results would seem to justify a larger clinical trial to assess the actual efficacy of this contraceptive method.
八名有排卵功能的女性参与了一种新型避孕方法的初步评估。该技术包括皮下植入一种能够控制释放左炔诺孕酮的可生物降解胶囊。研究涵盖了五个月经周期：三个观察周期以确认排卵情况，一个植入胶囊的周期，以及取出胶囊后的随访观察周期。所有有性生活的受试者在研究期间均采用屏障避孕法。在所有五个周期内都进行了基础体温测定，并且在最后三个周期中，于第5天、第8至18天以及第22天对促黄体生成素、促卵泡生成素、雌二醇、孕酮和左炔诺孕酮进行了血清检测。除一名受试者外，所有受试者在胶囊植入期间排卵均受到抑制。未出现严重不良反应。这些结果似乎证明有必要进行更大规模的临床试验，以评估这种避孕方法的实际效果。
